Recipharm and LIDDS have signed an exclusive collaboration for the scale-up of the production process and commercial manufacture of Liproca Depot, LIDDS prostate cancer treatment. The agreement plays part in the upcoming Phase IIb study planned to start in 2016. Recipharm has also invested SEK 5 million in a private placement, becoming the third largest shareholder of LIDDS.
 
“LIDDS’ technology platform is highly interesting as it potentially can be used for other, already approved therapies which may lead to shorter development time for new products. We are looking forward to collaborating with LIDDS through contributing our technical expertise within production, and thus delivering a more gentle treatment for prostate cancer patients in the future,” said Carl Johan Spak, executive vice president Development & Technology at Recipharm.
 
“We are very pleased that the agreement with Recipharm has been signed, as it is an important part of the preparations for the next clinical study. Recipharm is a well-reputed company with high quality, cost-effective processes for manufacturing. This agreement will strengthen the attraction for out-licensing of Liproca Depot,” said Monica Wallter chief executive officer of LIDDS.